Larimar Therapeutics price target raised to $16 from $15 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Larimar Therapeutics (LRMR) to $16 from $15 and keeps a Buy rating on the shares following the Q4 report. The firm says a submission for Nomlabofusp for accelerated approval is expected by the end of 2025.